1. Immunohistochemical expression of p53 in Type I and II epithelial ovarian cancer among Sudanese women: a cross-sectional study
   Aisha Osman Mohamed et al, 2019, F1000Research CrossRef
2. Estrogen Receptor-Beta2 (ERβ2)–Mutant p53–FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC)
   Chetan C. Oturkar et al, 2022, Cancers CrossRef
3. Targeted DNA sequencing of high‐grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression
   Petr Holý et al, 2024, International Journal of Cancer CrossRef
4. P53 and TLR4 expression are prognostic markers informing progression free survival of advanced stage high grade serous ovarian cancer
   Mark Bates et al, 2024, Pathology - Research and Practice CrossRef
5. The association between codon72 polymorphism of p53 gene and the risk of endometrial cancer: an updating meta-analysis
   Xinzi Lin et al, 2016, Archives of Gynecology and Obstetrics CrossRef
6. Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer
   Diana P. English et al, 2016, Expert Review of Molecular Diagnostics CrossRef
7. p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers
   Eric J. Devor et al, 2017, International Journal of Oncology CrossRef
8. A Review: Genetic Mutations as a Key to Unlocking Drug Resistance in Cervical Cancer
   Carla Eksteen et al, 2024, Cancer Control CrossRef
9. TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses
   Victoria Mandilaras et al, 2019, International Journal of Gynecologic Cancer CrossRef
10. Gain-of-Function Mutant TP53 R248Q Overexpressed in Epithelial Ovarian Carcinoma Alters AKT-Dependent Regulation of Intercellular Trafficking in Responses to EGFR/MDM2 Inhibitor
    Zih-Yin Lai et al, 2021, International Journal of Molecular Sciences CrossRef
11. Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy
    Viktor Hlaváč et al, 2022, Life Science Alliance CrossRef
12. Predicting tumour resistance to paclitaxel and carboplatin utilising genome‐wide screening in haploid human embryonic stem cells
    Jonathan Nissenbaum et al, 2024, Cell Proliferation CrossRef
13. Small Non-Coding-RNA in Gynecological Malignancies
    Shailendra Kumar Dhar Dwivedi et al, 2021, Cancers CrossRef
14. Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells
    Ugo Testa et al, 2018, Medicines CrossRef
15. Clinical Outcomes of TP53 Mutations in Cancers
    Ana I. Robles et al, 2016, Cold Spring Harbor Perspectives in Medicine CrossRef
16. TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma
    Lauren Montemorano et al, 2024, Gynecologic Oncology CrossRef
17. Ubiquitin ligase TRIM71 suppresses ovarian tumorigenesis by degrading mutant p53
    Yajie Chen et al, 2019, Cell Death & Disease CrossRef
18. Mutated p53 in HGSC—From a Common Mutation to a Target for Therapy
    Aya Saleh et al, 2021, Cancers CrossRef
19. TP53Mutations in Breast and Ovarian Cancer
    Laxmi Silwal-Pandit et al, 2017, Cold Spring Harbor Perspectives in Medicine CrossRef
20. Development of a necroptosis-related gene signature and the immune landscape in ovarian cancer
    Sipei Nie et al, 2023, Journal of Ovarian Research CrossRef
21. Variable Mutations at the p53-R273 Oncogenic Hotspot Position Leads to Altered Properties
    Ankush Garg et al, 2020, Biophysical Journal CrossRef
22. Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer
    Moito Iijima et al, 2017, Oncology Letters CrossRef
23. Comprehensive Collection of Whole-Slide Images and Genomic Profiles for Patients with Bladder Cancer
    Pei-Hang Xu et al, 2024, Scientific Data CrossRef
24. Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives
    Alka Singh et al, 2019, Frontiers in Cell and Developmental Biology CrossRef
25. The epigenetic correlation among ovarian cancer, endometriosis and PCOS: A review
    Harinee Throwba et al, 2022, Critical Reviews in Oncology/Hematology CrossRef
26. Expression of Nuclear Division Cycle 80 Complex Genes in Ovarian Cancer and Correlation with the Clinicopathological Features and Survival Outcomes
    Mai A. Nasser et al, 2024, Indian Journal of Gynecologic Oncology CrossRef
27. A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients
    Yingli Zhang et al, 2021, Scientific Reports CrossRef
28. Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)
    Marica Garziera et al, 2018, International Journal of Molecular Sciences CrossRef
29. TP53 DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer
    Hung-Chih Hsu et al, 2019, Cancers CrossRef
30. Insight updating of the molecular hallmarks in ovarian carcinoma
    Alba Mota et al, 2020, European Journal of Cancer Supplements CrossRef
31. Advanced Lung Adenocarcinoma Patient with ERBB2 Amplification Identified by Comprehensive Genomic Profiling Benefits from Trastuzumab
    Chi-Wei Tao et al, 2020, Case Reports in Oncological Medicine CrossRef
32. Capture‐based next‐generation sequencing reveals multiple actionable mutations in cancer patients failed in traditional testing
    Jing Xie et al, 2016, Molecular Genetics & Genomic Medicine CrossRef
33. Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations
    Isao Otsuka, 2021, International Journal of Molecular Sciences CrossRef
34. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach
    Marica Garziera et al, 2019, Cells CrossRef
35. Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations
    Talayeh S. Ghezelayagh et al, 2021, Gynecologic Oncology CrossRef
36. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer
    Åsa Fransson et al, 2016, Journal of Ovarian Research CrossRef
37. Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer
    Megan E. McDonald et al, 2019, International Journal of Molecular Sciences CrossRef
38. Genetic Alterations in Ovarian Cancer as Prognostic and Predictive Biomarkers of Therapy Response and Surgical Outcomes
    Khalid El Bairi et al, 2021, Ovarian Cancer Biomarkers CrossRef
39. Survival of patients with structurally-groupedTP53mutations in ovarian and breast cancers
    Brandon-Luke L. Seagle et al, 2015, Oncotarget CrossRef
40. Negative p53 Expression Confers Worse Prognosis in Patients With Resected Pancreatic Ductal Adenocarcinoma
    Bo Li et al, 2022, Pancreas CrossRef
41. Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC)
    Marica Garziera et al, 2019, Cells CrossRef
42. Whole-exome sequencing reveals critical genes underlying metastasis in oesophageal squamous cell carcinoma
    Wei Dai et al, 2017, The Journal of Pathology CrossRef
43. TP53 hot spot mutations in ovarian cancer: Selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas
    Brandon-Luke L. Seagle et al, 2015, Gynecologic Oncology CrossRef
44. Gene Expression Signature: An Influential Access to Drug Discovery in Ovarian Cancer
    Anam Beg et al, 2022, Computational Intelligence in Oncology CrossRef
45. TP53 mutations and survival in ovarian carcinoma patients receiving first‐line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV‐2 study
    Eliana Bignotti et al, 2024, International Journal of Cancer CrossRef
46. Shedding light on the dark genome: Insights into the genetic, CRISPR-based, and pharmacological dependencies of human cancers and disease aggressiveness
    Doris Kafita et al, 2023, PLOS ONE CrossRef
47. Controversies in Gynecologic Cancer Staging: An AJCC Cancer Staging Manual, Eighth Edition Perspective
    Ian S. Hagemann et al, 2018, AJSP: Reviews and Reports CrossRef
48. Confronting the Care Delivery Challenges Arising from Precision Medicine
    Elise C. Kohn et al, 2016, Frontiers in Oncology CrossRef
49. P53 marker expression in epithelial ovarian tumours in a centre in Nigeria – a descriptive study
    Andrew Olushola Anjorin et al, 2024, BMC Women's Health CrossRef
50. Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors
    S. Y. Cindy Yang et al, 2018, Genome Medicine CrossRef
51. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
    Martin Köbel et al, 2023, The Journal of Pathology: Clinical Research CrossRef
52. Characterization of a TP53 Somatic Variant of Unknown Function From an Ovarian Cancer Patient Using Organoid Culture and Computational Modeling
    JIANLING BI et al, 2020, Clinical Obstetrics & Gynecology CrossRef
53. Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations
    Xiangbing Meng et al, 2018, Disease Markers CrossRef
54. High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
    Michael-Antony Lisio et al, 2019, International Journal of Molecular Sciences CrossRef
55. TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
    Kristina W. Thiel et al, 2022, Journal of Clinical Oncology CrossRef
56. Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
    Ulyana A. Boyarskikh et al, 2020, Frontiers in Oncology CrossRef
57. Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers
    Katharina Bischof et al, 2019, Scientific Reports CrossRef
58. Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments
    Yaoqing Shen et al, 2019, Proceedings of the National Academy of Sciences CrossRef
59. Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets
    Rong Tan et al, 2024, British Journal of Cancer CrossRef